While other genes have been reported as potential markers for prognosis and indicators of sensitivity/resistance to drugs in CML, including TGF-β, TNF-α [44], vascular endothelial growth factor A (VEGFA) [45], and 53 (TP53) [46,47,48,49,50] pathways. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.